An Assessment of Statin Safety by Hepatologists

Published:February 06, 2006DOI:
      The purpose of the Liver Expert Panel was to provide advice to the National Lipid Association’s (NLA) Safety Task Force in response to specific questions concerning liver-associated risks of statin therapy. The panel was composed of academic hepatologists with clinical and research interests in nonalcoholic fatty liver disease, lipid metabolic disorders, and drug hepatotoxicity.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chalasani N.
        Statins and hepatotoxicity.
        Hepatology. 2005; 41: 690-695
      1. Lipitor (atorvastatin) [package insert]. Pfizer Inc, New York, NY2004
      2. Vytorin (ezetimibe-simvastatin) [package insert]. Merck/Schering-Plough Pharmaceuticals, North Wales, PA2005
      3. Zetia (ezetimibe) [package insert]. Merck/Schering-Plough Pharmaceuticals, North Wales, PA2005
        • Mofrad P.
        • Contos M.J.
        • Haque M.
        • Sargeant C.
        • Fisher R.A.
        • Luketic V.A.
        • Sterling R.K.
        • Shiffman M.L.
        • Stravitz R.T.
        • Sanyal A.J.
        Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.
        Hepatology. 2003; 37: 1286-1292
        • Sniderman A.D.
        Is there value in liver function test and creatine phosphokinase monitoring for statin use?.
        Am J Cardiol. 2004; 94: 30F-34F
        • Vuppalanchi R.
        • Teal E.
        • Chalasani N.
        Patients with elevated baseline liver enzymes do not have higher frequency of hepatoxicity from lovastatin than those with normal baseline liver enzymes.
        Am J Med Sci. 2005; 329: 62-65
        • Chalasani N.
        • Aljadhey H.
        • Kesterson J.
        • Murray M.D.
        • Hall S.D.
        Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.
        Gastroenterology. 2004; 126: 1287-1292
      4. Mevacor (lovastatin) [package insert]. Merck & Co. Inc, Whitehouse Station, NJ2005
      5. Zocor (simvastatin) [package insert]. Merck & Co. Inc, Whitehouse Station, NJ2004
      6. Lescol (fluvastatin) [package insert]. Novartis, East Hanover, NJ2003
      7. Pravachol (pravastatin) [package insert]. Bristol-Myers Squibb, Princeton, NJ2004
      8. Crestor (rosuvastatin) [package insert]. AstraZeneca, Wilmington, DE2005
        • de Denus S.
        • Spinler S.A.
        • Miller K.
        • Peterson A.M.
        Statins and liver toxicity.
        Pharmacotherapy. 2004; 24: 584-591
        • Russo M.W.
        • Galanko J.A.
        • Shrestha R.
        • Fried M.W.
        • Watkins P.
        Liver transplantation for acute liver failure from drug induced liver injury in the United States.
        Liver Transpl. 2004; 10: 1018-1023
        • Gotto A.M.
        Safety and statin therapy. Reconsidering the risks and benefits.
        Arch Intern Med. 2003; 163: 657-659
        • Law M.R.
        • Rudnicka A.R.
        Statin safety.
        Am J Cardiol. 2006; 97: 52C-60C
        • Pelli N.
        • Setti M.
        • Ceppa P.
        • Toncini C.
        • Indiveri F.
        Autoimmune hepatitis revealed by atorvastatin.
        Eur J Gastroenterol Hepatol. 2003; 15: 921-924
        • Siddiqui J.
        • Raina D.
        • Abraham A.
        • Alla V.
        • Chaslasani N.
        • Wu G.Y.
        • Bonkovsky H.L.
        Autoimmune hepatitis induced by statins.
        Gastroenterology. 2005; 128 ([abstract]): A171
        • Tolman K.G.
        The liver and lovastatin.
        Am J Cardiol. 2002; 89: 1374-1380
        • Smith C.C.
        • Bernstein L.I.
        • Davis R.B.
        • Rind D.M.
        • Shmerling R.H.
        Screening for statin-related toxicity.
        Arch Intern Med. 2003; 163: 688-692
        • Sandler R.S.
        • Everhart J.E.
        • Donowitz M.
        • Adams E.
        • Cronin K.
        • Goodman C.
        • Gemmen E.
        • Shah S.
        • Avdic A.
        • Rubin R.
        The burden of selected digestive diseases in the United States.
        Gastroenterology. 2002; 122: 1500-1511
        • Neuschwanter-Tetri B.A.
        • Caldwell S.H.
        Nonalcoholic steatohepatitis.
        Hepatology. 2003; 37: 1202-1219
        • Rallidis L.S.
        • Drakoulis C.K.
        • Parasi A.S.
        Pravastatin in patients with nonalcoholic steatohepatitis.
        Atherosclerosis. 2004; 174: 193-196
        • Horlander J.C.
        • Kwo P.Y.
        • Cummings O.W.
        • Koukoulis G.
        Atorvastatin for the treatment of NASH [abstract].
        Gastroenterology. 2001; 120: A544
        • Kiyici M.
        • Gulten M.
        • Gurel S.
        • et al.
        Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.
        Can J Gastroenterol. 2003; 17: 713-718
        • Zimmerman H.J.
        Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver. Appleton-Century-Crofts, New York1978 (181–185, 363–364)
        • Bjornsson E.
        • Olsson R.
        Outcome and prognostic markers in severe drug-induced liver disease.
        Hepatology. 2005; 42: 481-489
        • Senior J.R.
        Regulatory perspective.
        in: Kaplowitz N. DeLeve L.D. Drug Induced Liver Disease. Marcel Dekker, Inc, New York2003: 739-754